Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Hale

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2008
Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphologyDouglas A Meyer, Edmond Richer, Stanley A Benkovic, et al.
Frontiers in Immunology|March 24, 2023
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trialsPatrick M McCarthy, Franklin A Valdera, Todd R Smolinsky, et al.
Clinical Immunology (Orlando, Fla.)|January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancerR Connor Chick, G Travis Clifton, Diane F Hale, et al.
Human Gene Therapy|June 28, 2023
An Engineered Adeno-Associated Virus Capsid Mediates Efficient Transduction of Pericytes and Smooth Muscle Cells of the Brain VasculatureServio H Ramirez, Jonathan F Hale, Siobhan McCarthy, et al.
Cancer Medicine|July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsTommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.
Annals of Surgical Oncology|February 28, 2021
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary AnalysisTimothy J Vreeland, Guy T Clifton, Diane F Hale, et al.
Oncotarget|November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patientsDoreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
Breast Cancer Research and Treatment|April 24, 2020
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceTommy A Brown, Elizabeth A Mittendorf, Diane F Hale, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2008
Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphologyDouglas A Meyer, Edmond Richer, Stanley A Benkovic, et al.
Frontiers in Immunology|March 24, 2023
Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trialsPatrick M McCarthy, Franklin A Valdera, Todd R Smolinsky, et al.
Clinical Immunology (Orlando, Fla.)|January 24, 2021
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancerR Connor Chick, G Travis Clifton, Diane F Hale, et al.
Human Gene Therapy|June 28, 2023
An Engineered Adeno-Associated Virus Capsid Mediates Efficient Transduction of Pericytes and Smooth Muscle Cells of the Brain VasculatureServio H Ramirez, Jonathan F Hale, Siobhan McCarthy, et al.
Cancer Medicine|July 6, 2019
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patientsTommy A Brown, Kevin Byrd, Timothy J Vreeland, et al.
Annals of Surgical Oncology|February 28, 2021
A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary AnalysisTimothy J Vreeland, Guy T Clifton, Diane F Hale, et al.
Oncotarget|November 17, 2016
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patientsDoreen O Jackson, Kevin Byrd, Timothy J Vreeland, et al.
Melanoma Research|July 1, 2021
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanomaAlexandra M Adams, Robert C Chick, Timothy J Vreeland, et al.
Cancer Medicine|May 13, 2021
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysisRobert C Chick, Mark B Faries, Diane F Hale, et al.
Breast Cancer Research and Treatment|April 24, 2020
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrenceTommy A Brown, Elizabeth A Mittendorf, Diane F Hale, et al.
Pageof 14